Compare AbCellera Biologics Inc (ABCL) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Marathon Petroleum Corp — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Marathon Petroleum Corp trades at $279.38 (market cap $77.75B). The key difference: Marathon Petroleum Corp is far larger — about 33.1× AbCellera Biologics Inc's market cap, and Marathon Petroleum Corp pays a 1.47% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MPC | |
|---|---|---|
Market Cap | $2.35B | $77.75B |
Sector | Health | Energy |
52-Week High | $8.12 | $268.99 |
52-Week Low | $2.78 | $158.59 |
Enterprise Value | $1.99B | $109.93B |
Dividend Yield | — | 1.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Marathon Petroleum (MPC) trades at $266.33, showing minimal daily movement (-0.01%) but maintaining strong momentum with a 52% gain over the past six months. The stock demonstrates robust profitability with ROE of 27.92% and net income margin of 3.42%, supported by favorable refining margins from global supply disruptions. Recent earnings show mixed performance with Q3 2025 missing estimates but Q1 2026 beating expectations by 123%.
MPC presents a compelling investment case with attractive valuation (P/E 17.71, P/S 0.6) and strong analyst support (76% buy ratings). However, declining revenue trends from $177.5B in 2022 to $132.7B in 2025 and rising debt-to-asset ratio to 42.59% warrant caution. The upcoming Q2 2026 earnings on August 4th will be critical for validating the current bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
